In CML, various mutations associated with response to TKI and/or progression to accelerated phase or blast crisis have been reported, suggesting a role for additional mutations besides BCR::ABL1 in the evolution of CML disease [67•]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.